tbuckley/cabot-search huggingface dataset:
Abstract 9104: Pulmonary Endothelial Nedd9 and the Prothrombotic Pathophenotype of Acute Respiratory Distress Syndrome Due to Sars-cov-2 Infection
Authors: George A Alba, Andriy Samokhin, Lida P Hariri, Angela Shih, Kathleen J Haley, Robert F Padera, Sara O Vargas, Taylor Thompson, Richard N Mitchell, Bradley A Maron
Journal: Circulation (2021)

Background: The pathobiology of in situ pulmonary thrombosis in acute respiratory distress syndrome (ARDS) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is incompletely characterized. In human pulmonary artery endothelial cells (HPAECs), hypoxia upregulates expression of a pro-thrombotic NEDD9 peptide (N9 p ) on the extracellular plasma membrane surface. We hypothesized that increased pulmonary endothelial N9 p is a novel feature of the SARS-CoV-2 pathophenotype. Methods: Paraffin-embedded autopsy lung specimens were acquired from patients with ARDS due to SARS-CoV-2 infection (n=13), ARDS of other causes (n=10), and non-disease controls (n=5). Immunofluorescence characterized expression of N9 P , fibrin, and TCF12, a putative binding target of SARS-CoV-2 and known transcriptional regulator of NEDD9 . We performed RNA-Seq on mRNA isolated from control HPAECs treated with normoxia or hypoxia (0.2% O 2 ) for 24 hr. Immunoprecipitation-liquid chromatography-mass spectrometry (IP-LC-MS) profiled protein-protein interactions involving N9 p relevant to thrombus stabilization. Results: Compared to non-SARS-CoV-2-ARDS lungs, pulmonary endothelial N9 P expression and N9 P -fibrin colocalization was increased by 174% (P&lt;0.002) and 212% (P&lt;0.001) in SARS-CoV-2-ARDS, respectively. Compared to normoxia, hypoxia increased TCF12 mRNA quantity significantly in HPAECs in vitro [+1.19-fold, P=0.001; false discovery rate (FDR)=0.005]. Pulmonary endothelial nuclear TCF12 expression was also increased by 370% in SARS-CoV-2-ARDS vs. controls. In HPAEC plasma membranes, IP-LC-MS identified a novel protein-protein interaction between NEDD9 and the β3 subunit of the αvβ3 integrin, which regulates fibrin anchoring to endothelial cells. Conclusions: Compared to non-SARS-CoV-2-ARDS, SARS-CoV-2-ARDS is associated with increased pulmonary endothelial N9 p expression and N9 p -fibrin colocalization in microthrombi in situ . Increased hypoxia signaling or SARS-CoV-2-mediated regulation of TCF12 are potential mechanisms by which to explain these findings. Identifying N9 p in the pulmonary microthrombi of SARS-CoV-2 lungs may have important pathobiological and, potentially, therapeutic implications for ARDS patients.
MTHFD2 is a metabolic checkpoint controlling effector and regulatory T cell fate and function
Authors: Ayaka Sugiura, Gabriela Andrejeva, Kelsey Voss, Darren R. Heintzman, Xincheng Xu, Matthew Z. Madden, Xiang Ye, Katherine L. Beier, Nowrin U. Chowdhury, Melissa M. Wolf, Arissa C. Young, Dalton L. Greenwood, Allison E. Sewell, Shailesh K. Shahi, Samantha N. Freedman, Alanna M. Cameron, Patrik Foerch, Tim Bourne, Juan C. Garcia-Canaveras, John Karijolich, Dawn C. Newcomb, Ashutosh K. Mangalam, Joshua D. Rabinowitz, Jeffrey C. Rathmell
Journal: Immunity (2021)
Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia
Authors: Severine Cathelin, David Sharon, Amit Subedi, Dan Cojocari, Darren C. Phillips, Joel D. Leverson, Kyle J. MacBeth, Brandon Nicolay, Rohini Narayanaswamy, Sebastien Ronseaux, Guowen Liu, Steven M. Chan
Journal: Leukemia (2021)
Abstract PO-045: <b>Targeting HNF1A-dependent cell proliferation and stemness in PDAC using BET inhibitors</b>
Authors: Bharani Muppavarapu, Ethan Abel, Melanie Mayberry
Journal: Cancer Research (2021)

Abstract Pancreatic ductal adenocarcinoma (PDAC) is a disease with poor prognosis, with an overall survival rate of only 10%. Standard of care involves chemotherapy which improves survival by only a few weeks. Several barriers to therapeutic efficacy impede increasing survival outcome, including intrinsic resistance, owing to presence of therapy-resistant pancreatic cancer stem-like cells (PCSCs). Therefore, developing therapeutics to target molecular networks that maintain PCSC populations is critical. Microarray analysis from our lab previously established that pancreas lineage transcription factor HNF1A and its targets are enriched in CD44+CD24+EPCAM+ human PCSCs and that genetic depletion of HNF1A ablates this population and importantly, diminished tumor growth in primary PDAC xenografts. However, there are no therapeutics to directly target HNF1A. In this project, we propose to indirectly ablate HNF1A and its network by targeting epigenetic readers, bromodomain and extra-terminal domain protein family (BET) that maintain expression of transcription factor networks. We hypothesize that BET inhibitors decrease stemness and tumor growth in a HNF1A-dependent manner. Studies in our lab established that BET inhibitors decrease colony-formation, tumorsphere formation and cell-cycle progression in PDAC cells, that is rescued by overexpressing HNF1A. These results indicate that BET inhibitors decrease stemness and proliferation in pancreatic cancer cells in a HNF1A-dependent manner. These results suggest that BET inhibitors target multiple HNF1A-dependent tumor-promoting programs, such as stemness and tumor growth which could impact utilization of these drugs in clinical settings. The ultimate goal of our project is to provide rationale for the use of BET inhibitors in clinical setting in pancreatic cancer. Citation Format: Bharani Muppavarapu, Ethan Abel, Melanie Mayberry. Targeting HNF1A-dependent cell proliferation and stemness in PDAC using BET inhibitors [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PO-045.
<i>LIN28B</i> and <i>ZBTB8B</i> Genes Are Highly Expressed <i>in Vitro</i> in a CD34⁺ Cells Subpopulation of β-Thalassemia Major Patients and May be Involved in Increased HbF Production
Authors: Flávia Peixoto Albuquerque, Ingrid Grazielle Sousa, Bruno Batista Souza, Jersey Heitor da S Maués, Carolina Lanaro, Dulcinéia Martins de Albuquerque, Fernando Ferreira Costa
Journal: Blood (2021)
Abstract 10883: Cardiac-Oncology Prognostication and Outcomes in Female Breast Cancer Survivors
Authors: Joseph Heaton, Alyssa Salanga, Robert Massaro, Robert S Graebe
Journal: Circulation (2021)

Background: Heart disease risk and mortality is increased in breast cancer patients. Tumor and treatment factors have not been well described for cardiac mortality prognostication. We evaluated presenting characteristics and treatment factors on cardiac mortality in breast cancer survivors. Methods: The Surveillance, Epidemiology and End Results (SEER) registry was queried for adult female patients with malignant breast cancer from 1990-2016, who survived more than 60 months. Results: The SEER registry identified 686,559 patients. The average patient was white (83.3%), married (58.0%), and 59.9 ± 13.3 years. The typical tumor on presentation was moderately differentiated (38.7%), localized (55.2%), ER positive (71.2%), PR positive (60.3%), and HER status unknown (87.0%). Median survival times for cardiac-specific mortality was 117 months compared to 98 months for recurring breast cancer (log rank P &lt; 0.001). Adjusted Cox proportional hazard models in Table 1 revealed increased cardiac-specific mortality with HER positive status and increasing age. Decreased mortality was noted in married or widowed patients and after selected multimodal therapies. Race, tumor grade, and localization were not well correlated. Conclusion: Breast cancer survivors are at risk for heart disease and cardiac mortality. After five years, the initial tumor burden does not correlate well with cardiac outcomes. Multimodal therapy and marriage were associated with significantly reduced risk. Table 1. Cox Proportional Hazards Hazard ratios for cardiac-specific mortality.
A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Authors: Ramzi Abboud, Feng Gao, Michael P. Rettig, Jeremy Eisele, Leah Gehrs, Nichols Wallace, Camille Abboud, Peter Westervelt, Geoffrey L. Uy, Amanda F. Cashen, Matt Christopher, Armin Ghobadi, Meagan A. Jacoby, Iskra Pusic, Keith E. Stockerl-Goldstein, John F. DiPersio, Mark A. Schroeder
Journal: Blood (2021)
Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment
Authors: Muhamed Baljevic, Cristina Gasparetto, Gary J. Schiller, Sascha A. Tuchman, Natalie S. Callander, Suzanne Lentzsch, Jorge Monge, Rami Kotb, Nizar J. Bahlis, Darrell White, Christine I. Chen, Heather J. Sutherland, Sumit Madan, Richard Leblanc, Michael Sebag, Christopher P. Venner, William I. Bensinger, Noa Biran, Andrew DeCastro, Dane R. Van Domelen, Ohad S. Bentur, Chris Zhang, Jatin J. Shah, Sharon Shacham, Michael G. Kauffman, Brea Lipe
Journal: Blood (2021)
Multiplexed Ion Beam Imaging: Insights into Pathobiology
Authors: Candace C. Liu, Erin F. McCaffrey, Noah F. Greenwald, Erin Soon, Tyler Risom, Kausalia Vijayaragavan, John-Paul Oliveria, Dunja Mrdjen, Marc Bosse, Dmitry Tebaykin, Sean C. Bendall, Michael Angelo
Journal: Annual Review of Pathology Mechanisms of Disease (2021)

Next-generation tools for multiplexed imaging have driven a new wave of innovation in understanding how single-cell function and tissue structure are interrelated. In previous work, we developed multiplexed ion beam imaging by time of flight, a highly multiplexed platform that uses secondary ion mass spectrometry to image dozens of antibodies tagged with metal reporters. As instrument throughput has increased, the breadth and depth of imaging data have increased as well. To extract meaningful information from these data, we have developed tools for cell identification, cell classification, and spatial analysis. In this review, we discuss these tools and provide examples of their application in various contexts, including ductal carcinoma in situ, tuberculosis, and Alzheimer's disease. We hope the synergy between multiplexed imaging and automated image analysis will drive a new era in anatomic pathology and personalized medicine wherein quantitative spatial signatures are used routinely for more accurate diagnosis, prognosis, and therapeutic selection.
Evaluating Front Line Treatment Regimens for Waldenstrom Macroglobulinaemia: A Systematic Review and Meta-Analysis
Authors: Wee Lee William Chan, Vanessa CL Chong, Ian JY Wee, Anand Jeyasekharan, Michelle Poon, Hian Li Esther Chan, Joanne Lee, Yen Lin Chee, Wee-Joo Chng, Miny Samuel, Sanjay de Mel
Journal: Blood (2021)
CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL
Authors: Noelle V Frey, Saar Gill, Wei-Ting Hwang, Selina M. Luger, Mary Ellen Martin, Shannon R. McCurdy, Alison W. Loren, Keith W. Pratz, Alexander E. Perl, Julie Barber-Rotenberg, Amy Marshall, Marco Ruella, Simon F Lacey, Joseph Fraietta, Andrew Fesnak, Megan O'brien, Theresa Schanne, Jennifer L Brogdon, Boris Engels, Bruce L Levine, Carl H June, David L Porter, Elizabeth O. Hexner
Journal: Blood (2021)
Non-Genetic Determinants of Clonotypic T Cell Expansion Following Allogeneic Stem Cell Transplant
Authors: Albert Yeh, Motoko Koyama, Simone A Minnie, Julie Boiko, Kathleen S Ensbey, Christine R Schmidt, Sam Legg, Gabriela Campoy, Ethan Nelson, Phil Bradley, Geoff R. Hill
Journal: Blood (2021)
Hematopoietic Stem Cells Undergo Immune Training and Constitute a Long-Term Reservoir for Hyper-Inflammatory Macrophages in a Mouse Model of Chronic Autoimmunity
Authors: Taylor S Mills, Bailee N. Kain, Erin D Lucas, Matthew T Burchill, Beth A Jiron Tamburini, Katherine Y. King, Eric Pietras
Journal: Blood (2021)
Abstract 11130: Impact of the Covid-19 Pandemic on the Epidemiology of Out-of-hospital Cardiac Arrest: A Systematic Review and Meta-Analysis
Authors: Seth E Teoh, Yoshio Masuda, Darren J Tan, Nan Liu, Laurie Morrison, Marcus E Ong, Audrey L Blewer, Andrew Ho
Journal: Circulation (2021)

Introduction: The coronavirus disease 2019 (COVID-19) pandemic has influenced epidemiology through direct and indirect effects, yet the impact on out-of-hospital cardiac arrest (OHCA) is unclear. We aimed to evaluate the impact of the pandemic on the incidence, characteristics, and clinical outcomes of OHCA. Hypothesis: We hypothesized that compared to the pre-pandemic period, the COVID-19 pandemic period was associated with increased incidence and case fatality rate (CFR) of OHCA, as well as decreased rates of intermediate clinical outcomes (termination of resuscitation [TOR], return of spontaneous circulation [ROSC], survival to hospital admission, and survival to hospital discharge). We further postulated that there was a change in the etiologies of OHCA during the pandemic as well as a decline in the rate of shockable rhythm as the initial presenting rhythm. Methods: In this systematic review and meta-analysis, five scientific databases were searched from inception to May 3, 2021. Meta-analyses were performed for the primary outcomes, secondary outcomes, and clinical characteristics. This study was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42021253879). Results: The search yielded 966 articles. 20 articles were included for analysis. The COVID-19 pandemic was associated with a 39.5% increase in pooled annual OHCA incidence (p&lt;0.001). Pooled CFR was increased by 2.65% (p&lt;0.001), with an odds ratio (OR) of 1.95 for mortality (95% confidence interval [95%CI] 1.51-2.51). There was increased field TOR (OR=2.46, 95%CI 1.62-3.74). There were decreased ROSC (OR=0.65, 95%CI 0.55-0.77), survival to hospital admission (OR=0.65, 95%CI 0.48-0.89), and survival to discharge (OR=0.52, 95%CI 0.40-0.69). There was decreased shockable rhythm (OR=0.73, 95%CI 0.60-0.88) and increased asphyxial etiology of OHCA (OR=1.17, 95%CI 1.02-1.33). There was moderate-to-high statistical heterogeneity. Findings were robust to sensitivity analyses, with no publication bias detected. Conclusions: The COVID-19 pandemic was associated with significant changes in OHCA epidemiology. Compared to the pre-pandemic period, the pandemic period was associated with increased OHCA incidence and worse outcomes.
Monitoring of Plasma Ferritin Levels after Blood Transfusions in Patients with Myelodysplastic Syndromes
Authors: Johanne Rozema, Ivar Van Asten, Beau Kwant, Robby E Kibbelaar, Nic J.G.M. Veeger, Harry De Wit, Eric N. Van Roon, Mels Hoogendoorn
Journal: Blood (2021)
Long-Term Subgroup Analyses from Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry
Authors: Jorge Labrador, Adolfo de la Fuente, David Martínez-Cuadrón, Rebeca Rodríguez-Veiga, Josefina Serrano, Mar Tormo, Jose Pérez-Simón, Fernando Ramos, Teresa Bernal del Castillo, Maria López-Pavía, Fernanda Trigo, Pilar Martinez Sanchez, Juan Ignacio Rodriguez-Gutierrez, Carlos Rodriguez, Cristina Gil, Daniel Garcia, Susana Vives, Maria Angeles Foncillas, Manuel Perez Encinas, Andrés Novo, Isabel Recio, Gabriela Rodriguez Macias, Juan Miguel Bergua Burgues, Victor Noriega Concepcion, Esperanza Lavilla, Alicia Roldán Pérez, Miguel A. Sanz, Pau Montesinos
Journal: Blood (2021)
Abstract 13140: Eicosapentaenoic Acid (EPA) Restores Pulmonary Endothelial Nitric Oxide Bioavailability Following Exposure to Urban Air Pollution Small Particles
Authors: Samuel Sherratt, Hazem Dawoud, Peter Libby, Deepak L Bhatt, Tadeusz Malinski, Preston Mason
Journal: Circulation (2021)

Introduction: Air pollution is the fourth leading contributor to global mortality. Cardiovascular (CV) disease accounts for the majority of these deaths, including stroke and myocardial infarction. The omega-3 fatty acid (n3FA) eicosapentaenoic acid (EPA) has vascular benefits that may contribute to reduced events in patients with CV risk (REDUCE-IT). Loss of endothelial cell (EC) nitric oxide (NO) bioavailability can favor thrombosis, vasoconstriction, and inflammation. We measured the effects of EPA on EC function during exposure to urban pollutant small particles (SPs). Methods: Pulmonary ECs (PECs) were pretreated with EPA (40 μM) for 2 h before addition of SPs with a diameter range of 1.35 to 30.1 μm from collected urban air (St. Louis, MO) for 2 h (50 μg/mL). Cells were stimulated with calcium ionophore to measure the time-dependent production of nitric oxide (NO) and peroxynitrite (ONOO – ) using tandem porphyrinic nanosensors; the ratio of NO to ONOO – is a measure of NO synthase coupling efficiency. Levels of soluble intercellular adhesion molecule-1 (sICAM-1) were also measured using immunochemistry (ELISA). Results: ECs challenged with urban SPs showed a reduction in NO release by 13% compared with control (373 ± 10 vs 428 ± 18 nM). An increase in ONOO – release by 52% (262 ± 17 vs 172 ± 14; p &lt;0.001) accompanied this drop in NO. The NO/ONOO – release ratio thus fell by 43% (1.43 ± 0.09 vs 2.49 ± 0.10; p &lt;0.001) following SP exposure. ECs treated with EPA had a greater NO/ONOO – release ratio by 31% ( p &lt;0.01) due to an increase in NO release by 5% and decrease in ONOO – release by 20% ( p &lt;0.01) compared with vehicle. Challenge with the SPs caused a 70% increase in sICAM-1 levels ( p &lt;0.05), while treatment with EPA attenuated sICAM-1 levels compared with SP alone (60%, p &lt;0.05). Conclusions: EPA significantly improved pulmonary EC function under conditions of inflammation caused by air pollution particles, including reductions in nitroxidative stress and the adhesion molecule ICAM-1. These effects of EPA in pulmonary tissue challenged with air particulate matter indicate a novel benefit for people exposed to air pollution.
The GA4GH Variation Representation Specification: A computational framework for variation representation and federated identification
Authors: Alex H. Wagner, Lawrence Babb, Gil Alterovitz, Michael Baudis, Matthew Brush, Daniel L. Cameron, Melissa Cline, Malachi Griffith, Obi L. Griffith, Sarah E. Hunt, David Kreda, Jennifer M. Lee, Stephanie Li, Javier Lopez, Eric Moyer, Tristan Nelson, Ronak Y. Patel, Kevin Riehle, Peter N. Robinson, Shawn Rynearson, Helen Schuilenburg, Kirill Tsukanov, Brian Walsh, Melissa Konopko, Heidi L. Rehm, Andrew D. Yates, Robert R. Freimuth, Reece K. Hart
Journal: Cell Genomics (2021)

Maximizing the personal, public, research, and clinical value of genomic information will require the reliable exchange of genetic variation data. We report here the Variation Representation Specification (VRS, pronounced "verse"), an extensible framework for the computable representation of variation that complements contemporary human-readable and flat file standards for genomic variation representation. VRS provides semantically precise representations of variation and leverages this design to enable federated identification of biomolecular variation with globally consistent and unique computed identifiers. The VRS framework includes a terminology and information model, machine-readable schema, data sharing conventions, and a reference implementation, each of which is intended to be broadly useful and freely available for community use. VRS was developed by a partnership among national information resource providers, public initiatives, and diagnostic testing laboratories under the auspices of the Global Alliance for Genomics and Health (GA4GH).
Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
Authors: Efstathios Kastritis, Monique C. Minnema, Meletios A. Dimopoulos, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Antoine Huart, Karim Belhadj, Alexandros Leonidakis, Kyriaki Manousou, Pieter Sonneveld, Giovanni Palladini
Journal: Blood (2021)
Subcutaneous Epcoritamab in Combination with R 2 (Rituximab and Lenalidomide) in Patients with Relapsed or Refractory Follicular Lymphoma: Preliminary Results from a Phase 1/2 Trial
Authors: Kim M Linton, Björn Wahlin, Sirpa Leepä, Franck Morschhauser, Brian Elliot, Tracy Liu, Mariana Cota Stirner, Aqeel Abbas, Lorenzo Falchi
Journal: Blood (2021)
Nebulised liposomal amphotericin-B as maintenance therapy in allergic bronchopulmonary aspergillosis: a randomised, multicentre trial
Authors: Cendrine Godet, Francis Couturaud, Sylvain Marchand-Adam, Christophe Pison, Frédéric Gagnadoux, Elodie Blanchard, Camille Taillé, Bruno Philippe, Sandrine Hirschi, Claire Andréjak, Arnaud Bourdin, Cécile Chenivesse, Stéphane Dominique, Laurence Bassinet, Marlène Murris-Espin, Frédéric Rivière, Gilles Garcia, Denis Caillaud, François-Xavier Blanc, François Goupil, Anne Bergeron, Anne Gondouin, Jean-Pierre Frat, Thomas Flament, Boubou Camara, Pascaline Priou, Anne-Laure Brun, François Laurent, Stéphanie Ragot, Jacques Cadranel, C. Godet, F. Couturaud, J. Cadranel, J-P. Frat, A-L. Brun, F. Laurent, S. Marchand-Adam, C. Pison, F. Gagnadoux, E. Blanchard, C. Taillé, B. Philippe, S. Hirschi, C. Andréjak, C. Chenivesse, S. Dominique, L. Bassinet, M. Murris-Espin, F. Rivière, G. Garcia, D. Caillaud, F-X. Blanc, F. Goupil, A. Gondouin, T. Flament, B. Camara, P. Priou, S. Ragot
Journal: European Respiratory Journal (2021)

Background In allergic bronchopulmonary aspergillosis (ABPA), prolonged nebulised antifungal treatment may be a strategy for maintaining remission. Methods We performed a randomised, single-blind, clinical trial in 30 centres. Patients with controlled ABPA after 4-month attack treatment (corticosteroids and itraconazole) were randomly assigned to nebulised liposomal amphotericin-B or placebo for 6 months. The primary outcome was occurrence of a first severe clinical exacerbation within 24 months following randomisation. Secondary outcomes included the median time to first severe clinical exacerbation, number of severe clinical exacerbations per patient, ABPA-related biological parameters. Results Among 174 enrolled patients with ABPA from March 2015 through July 2017, 139 were controlled after 4-month attack treatment and were randomised. The primary outcome occurred in 33 (50.8%) out of 65 patients in the nebulised liposomal amphotericin-B group and 38 (51.3%) out of 74 in the placebo group (absolute difference −0.6%, 95% CI −16.8– +15.6%; OR 0.98, 95% CI 0.50–1.90; p=0.95). The median (interquartile range) time to first severe clinical exacerbation was longer in the liposomal amphotericin-B group: 337 days (168–476 days) versus 177 days (64–288 days). At the end of maintenance therapy, total immunoglobulin-E and Aspergillus precipitins were significantly decreased in the nebulised liposomal amphotericin-B group. Conclusions In ABPA, maintenance therapy using nebulised liposomal amphotericin-B did not reduce the risk of severe clinical exacerbation. The presence of some positive secondary outcomes creates clinical equipoise for further research.
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study
Authors: Nazir Ahmed Ismail, Shaheed Vally Omar, Harry Moultrie, Zaheda Bhyat, Francesca Conradie, M Enwerem, Hannetjie Ferreira, Jennifer Hughes, Lavania Joseph, Yulene Kock, Vancy Letsaolo, Gary Maartens, Graeme Meintjes, Dumisani Ngcamu, Nana Okozi, Xavier Padanilam, Anja Reuter, Rodolf Romero, Simon Schaaf, Julian te Riele, Ebrahim Variava, Minty van der Meulen, Farzana Ismail, Norbert Ndjeka
Journal: The Lancet Infectious Diseases (2021)
Autoantibodies Against Type I IFNs in Patients with Ph-Negative Myeloproliferative Neoplasms
Authors: Oscar Borsani, Paul Bastard, Jérémie Rosain, Adrian Gervais, Emanuela Sant'Antonio, Daniele Vanni, Ilaria Carola Casetti, Daniela Pietra, Chiara Trotti, Virginia Valeria Ferretti, Luca Malcovati, Luca Arcaini, Alessandro Borghesi, Jean-Laurent Casanova, Elisa Rumi
Journal: Blood (2021)